BRISBANE, Australia — August 25, 2025 — BiotechReporter.news — Vaxxas Pty Ltd, a biotechnology company, has secured approximately $90 million in its latest financing round. The funds will be used to scale up production of its needle-free vaccination delivery technology.
The financing includes $49.22 million in new Series D equity and $40 million in debt facilities. The equity financing was led by SPRIM Global Investments, with participation from LGT Crestone, OneVentures, and Brandon Capital-Hostplus.
The funding will enable Vaxxas to accelerate the development and scale-up of its HD-MAP technology towards market readiness. David Hoey will transition to a new role as Strategic Advisor.
Vaxxas’ HD-MAP technology enables needle-free administration that reduces temperature control requirements for vaccine storage and creates opportunities for self-administration.
Contact: Amy Miller amymi@wecommunications.com +61 431 072 422
Source: Vaxxas
